These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 3113722

  • 1. Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer.
    Balkwill FR, Ward BG, Moodie E, Fiers W.
    Cancer Res; 1987 Sep 15; 47(18):4755-8. PubMed ID: 3113722
    [Abstract] [Full Text] [Related]

  • 2. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons.
    Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W.
    Cancer Res; 1986 Aug 15; 46(8):3990-3. PubMed ID: 2425938
    [Abstract] [Full Text] [Related]

  • 3. Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.
    Gridley DS, Slater JM, Stickney DR.
    J Biol Response Mod; 1989 Dec 15; 8(6):593-602. PubMed ID: 2513378
    [Abstract] [Full Text] [Related]

  • 4. Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft.
    Noviello E, Cimoli G, Cosimi A, Allievi E, Galletti P, Parodi S, Russo P.
    Cytokine; 1996 Apr 15; 8(4):330-3. PubMed ID: 9162224
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice.
    Kondo H, Tanaka N, Naomoto Y, Orita K.
    Jpn J Cancer Res; 1987 Nov 15; 78(11):1258-65. PubMed ID: 3121561
    [Abstract] [Full Text] [Related]

  • 6. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
    Furrer M, Altermatt HJ, Ris HB, Althaus U, Rüegg C, Liénard D, Lejeune FJ.
    Melanoma Res; 1997 Aug 15; 7 Suppl 2():S43-9. PubMed ID: 9578416
    [Abstract] [Full Text] [Related]

  • 7. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL, Stampfl S, Zimmerman RJ.
    Cancer Res; 1987 Aug 01; 47(15):3948-53. PubMed ID: 3496953
    [Abstract] [Full Text] [Related]

  • 8. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK, Mulé JJ, Krosnick JA, Rosenberg SA.
    Cancer Res; 1989 Mar 15; 49(6):1408-14. PubMed ID: 2784349
    [Abstract] [Full Text] [Related]

  • 9. Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice.
    Zhao E, Zhou M, Fu C, Shen B, Zhang Q, Lian L.
    Chin Med J (Engl); 1995 Aug 15; 108(8):571-5. PubMed ID: 7587485
    [Abstract] [Full Text] [Related]

  • 10. [An in vitro and in vivo study of antitumor effects of rHTNF-alpha on human ovarian cancer].
    Zhao EF, Zhou MQ, Fu CY.
    Zhonghua Zhong Liu Za Zhi; 1994 Jul 15; 16(4):273-6. PubMed ID: 7805556
    [Abstract] [Full Text] [Related]

  • 11. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
    Kong B, Wang W, Liu C, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Jiang S.
    Zhonghua Yi Xue Za Zhi; 2002 Sep 10; 82(17):1207-10. PubMed ID: 12475412
    [Abstract] [Full Text] [Related]

  • 12. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.
    Creasey AA, Reynolds MT, Laird W.
    Cancer Res; 1986 Nov 10; 46(11):5687-90. PubMed ID: 3756916
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
    Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z, Sun FX, Hoffman RM.
    Clin Cancer Res; 1999 Aug 10; 5(8):2157-63. PubMed ID: 10473100
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.
    Cancer Chemother Pharmacol; 2002 Dec 10; 50(6):501-8. PubMed ID: 12451478
    [Abstract] [Full Text] [Related]

  • 15. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
    Song K, Cowan KH, Sinha BK.
    Oncol Res; 1999 Dec 10; 11(3):153-9. PubMed ID: 10527075
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of the antitumor activity of recombinant human gamma-interferon employing human melanoma xenografts in athymic nude mice.
    Trotta PP, Harrison SD.
    Cancer Res; 1987 Oct 15; 47(20):5347-53. PubMed ID: 3115565
    [Abstract] [Full Text] [Related]

  • 20. Cytokines and pancreatic cancer. Sensitivity of xenotransplants of predominantly pancreatic carcinomas to rIFN-gamma and rTFN-alpha in nude mice.
    Kühl JS, Klapdor R, Bahlo M, Franke N, Kunde C, Arps H, Dietel M.
    Int J Pancreatol; 1989 Apr 15; 4(3):303-19. PubMed ID: 2503584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.